Biovica International AB (publ)

Stockholm Stock Exchange BIOVIC-B.ST

Biovica International AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 23.67

Biovica International AB (publ) Price to Sales Ratio (P/S) is 23.67 on January 14, 2025, a -58.27% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Biovica International AB (publ) 52-week high Price to Sales Ratio (P/S) is 74.78 on March 12, 2024, which is 216.00% above the current Price to Sales Ratio (P/S).
  • Biovica International AB (publ) 52-week low Price to Sales Ratio (P/S) is 20.98 on May 14, 2024, which is -11.33% below the current Price to Sales Ratio (P/S).
  • Biovica International AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 41.51.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
Stockholm Stock Exchange: BIOVIC-B.ST

Biovica International AB (publ)

CEO Mr. Anders Rylander
IPO Date March 29, 2017
Location Sweden
Headquarters Dag HammarskjOelds vAeg 54B
Employees 27
Sector Health Care
Industries
Description

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Similar companies

BIOA-B.ST

BioArctic AB (publ)

USD 17.87

3.09%

HNSA.ST

Hansa Biopharma AB (publ)

USD 2.91

-2.20%

CANTA.ST

Cantargia AB (publ)

USD 0.15

0.09%

StockViz Staff

January 15, 2025

Any question? Send us an email